Jiangsu Aidea Pharmaceutical Group

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
HIV integraseSmall molecule
HIV
Phase 1
HIV reverse transcriptaseSmall molecule
HIV

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
ACC017Phase 1/2Infection, Human Immunodeficiency Virus
Est. primary completion 2027-06-30 · NCT07711210 · CT.gov ↗
What to watch
2028 (1)
August 2028 (1)
ACC017Phase 3Infection, Human Immunodeficiency Virus
Est. primary completion 2028-08-31 · NCT07711223 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.